Survival comparison between glioblastoma multiforme and other incurable cancers
- PMID: 20167494
- DOI: 10.1016/j.jocn.2009.09.004
Survival comparison between glioblastoma multiforme and other incurable cancers
Abstract
Glioblastoma multiforme (GBM) is an incurable disease that has a reputation as having one of the worst prognoses of all cancers. Recent advances in treatment have led to significant improvements in both progression-free and overall survival. Despite this, the wider medical community continues to perceive GBM as having an incomparably poor prognosis. This perception may stem from a lack of awareness regarding the significant survival advantage through the addition of concurrent and post-radiotherapy temozolomide, as well as unfair comparisons to cancers with curable early stages. In this analysis, we compared the efficacy data reported in pivotal studies for the incurable stage of common cancers to modern efficacy data for GBM. In particular, we compared median overall survival, median progression-free survival and 12-month and 5-year survival rates. Our results demonstrate that with modern treatment, GBM survival is now comparable to, if not better than, many other incurable cancers.
(c) 2009. Published by Elsevier Ltd. All rights reserved.
Similar articles
-
Glioblastoma multiforme with oligodendroglial component (GBMO): favorable outcome after post-operative radiotherapy and chemotherapy with nimustine (ACNU) and teniposide (VM26).BMC Cancer. 2006 Oct 18;6:247. doi: 10.1186/1471-2407-6-247. BMC Cancer. 2006. PMID: 17049083 Free PMC article.
-
Intralesional lymphokine-activated killer cells as adjuvant therapy for primary glioblastoma.J Immunother. 2009 Nov-Dec;32(9):914-9. doi: 10.1097/CJI.0b013e3181b2910f. J Immunother. 2009. PMID: 19816190 Clinical Trial.
-
Glioblastoma multiforme: evidence-based approach to therapy.Expert Rev Anticancer Ther. 2007 Dec;7(12 Suppl):S23-7. doi: 10.1586/14737140.7.12s.S23. Expert Rev Anticancer Ther. 2007. PMID: 18076314 Review.
-
A review of the treatment and survival rates of 138 patients with glioblastoma multiforme.W V Med J. 1996 Jul-Aug;92(4):186-90. W V Med J. 1996. PMID: 8772403
-
Clinical trials for glioblastoma multiforme using adenoviral vectors.Curr Opin Mol Ther. 2009 Oct;11(5):485-92. Curr Opin Mol Ther. 2009. PMID: 19806496 Review.
Cited by
-
Stabilization of KPNB1 by deubiquitinase USP7 promotes glioblastoma progression through the YBX1-NLGN3 axis.J Exp Clin Cancer Res. 2024 Jan 23;43(1):28. doi: 10.1186/s13046-024-02954-8. J Exp Clin Cancer Res. 2024. PMID: 38254206 Free PMC article.
-
Epidemiology of Glioblastoma Multiforme-Literature Review.Cancers (Basel). 2022 May 13;14(10):2412. doi: 10.3390/cancers14102412. Cancers (Basel). 2022. PMID: 35626018 Free PMC article. Review.
-
The clinical utility of microRNA-21 as novel biomarker for diagnosing human cancers.Tumour Biol. 2015 Mar;36(3):1993-2005. doi: 10.1007/s13277-014-2806-z. Epub 2014 Nov 28. Tumour Biol. 2015. PMID: 25431259
-
miR-340 predicts glioblastoma survival and modulates key cancer hallmarks through down-regulation of NRAS.Oncotarget. 2016 Apr 12;7(15):19531-47. doi: 10.18632/oncotarget.6968. Oncotarget. 2016. PMID: 26799668 Free PMC article.
-
The Future Glioblastoma Clinical Trials Landscape: Early Phase 0, Window of Opportunity, and Adaptive Phase I-III Studies.Curr Oncol Rep. 2023 Sep;25(9):1047-1055. doi: 10.1007/s11912-023-01433-1. Epub 2023 Jul 4. Curr Oncol Rep. 2023. PMID: 37402043 Free PMC article. Review.
Publication types
MeSH terms
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical